SEARCH:   Advanced

Blood, 15 February 2005, Vol. 105, No. 4, pp. 1694-1698. Prepublished online as a Blood First Edition Paper on October 5, 2004; DOI 10.1182/blood-2004-08-3335. This Article Full Text (PDF) All Versions of this Article: 2004-08-3335v1 105/4/1694    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nuckel, H. Articles by Grosse-Wilde, H. Search for Related Content PubMed PubMed Citation Articles by Nuckel, H. Articles by Grosse-Wilde, H. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 27, 2004 Accepted September 30, 2004 HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia Holger Nuckel*, Vera Rebmann, Jan Durig, Ulrich Duhrsen, and Hans Grosse-Wilde Department of Hematology, Medical Faculty, University of Duisburg-Essen, Essen, Germany Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Essen, Germany * Corresponding author; email: holger.nueckel{at}uni-essen.de. The human leukocyte antigen (HLA)-G molecule exhibits limited tissue distribution and exerts multiple immunoregulatory functions. Recent studies indicate an ectopic up-regulation in tumor cells which may favor their escape from anti-tumor immune responses. The role of HLA-G in B-cell chronic lymphocytic leukemia (B-CLL) has not been defined. HLA-G expression was studied retrospectively in circulating B-CLL cells from 47 patients by flow cytometry using the MEM/G9 monoclonal antibody. The proportion of leukemic cells expressing HLA-G varied from 1% to 54%. Patients with 23% HLA-G positive cells (according to ROC-analysis; designated as HLA-G negative group) had a significantly longer progression-free survival (PFS) time than patients with >23% positive cells (median PFS: 120 versus 23 months, p=0.0001). In multivariate analysis HLA-G expression (hazard ratio 4.8; p=0.002) was an even better independent prognostic factor than the ZAP-70 or CD38 status. Humoral and cellular immunosuppression was significantly more prominent in HLA-G positive as compared to HLA-G negative patients group. In B-CLL the level of HLA-G expression is correlated with the degree of immunosuppression and prognosis. HLA-G may contribute to the impairment of immune responses against tumor cells and infections. Thus, these findings need to be confirmed in a prospective study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Yong Wook Jung, Young Tae Kim, Sang Wun Kim, S. Kim, Jae Hoon Kim, Nam Hoon Cho, and Jae Wook Kim Correlation of Human Leukocyte Antigen-G (HLA-G) Expression and Disease Progression in Epithelial Ovarian Cancer Reproductive Sciences, November 1, 2009; 16(11): 1103 - 1111. [Abstract] [PDF] E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. LeMaoult Beyond the increasing complexity of the immunomodulatory HLA-G molecule Blood, May 15, 2008; 111(10): 4862 - 4870. [Abstract] [Full Text] [PDF] C. Dearden Disease-Specific Complications of Chronic Lymphocytic Leukemia Hematology, January 1, 2008; 2008(1): 450 - 456. [Abstract] [Full Text] [PDF] A. Naji, S. Le Rond, A. Durrbach, I. Krawice-Radanne, C. Creput, M. Daouya, J. Caumartin, J. LeMaoult, E. D. Carosella, and N. Rouas-Freiss CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance Blood, December 1, 2007; 110(12): 3936 - 3948. [Abstract] [Full Text] [PDF] A. Lin, W.-H. Yan, H.-H. Xu, M.-F. Gan, J.-F. Cai, M. Zhu, and M.-Y. Zhou HLA-G expression in human ovarian carcinoma counteracts NK cell function Ann. Onc., November 1, 2007; 18(11): 1804 - 1809. [Abstract] [Full Text] [PDF] E. Lech-Maranda, P. Juszczynski, A. Szmigielska-Kaplon, K. Jamroziak, E. Balcerczak, and T. Robak Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia Haematologica, May 1, 2007; 92(5): 710 - 711. [Abstract] [Full Text] [PDF] J. LeMaoult, J. Caumartin, M. Daouya, B. Favier, S. L. Rond, A. Gonzalez, and E. D. Carosella Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells Blood, March 1, 2007; 109(5): 2040 - 2048. [Abstract] [Full Text] [PDF] N. Rouas-Freiss, P. Moreau, S. Ferrone, and E. D. Carosella HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism? Cancer Res., November 15, 2005; 65(22): 10139 - 10144. [Abstract] [Full Text] [PDF] X. Leleu, G. Le Friec, T. Facon, L. Amiot, R. Fauchet, B. Hennache, V. Coiteux, I. Yakoub-Agha, S. Dubucquoi, H. Avet-Loiseau, et al. Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Clin. Cancer Res., October 15, 2005; 11(20): 7297 - 7303. [Abstract] [Full Text] [PDF] J. LeMaoult, N. Rouas-Freiss, and E. D. Carosella HLA-G5 expression by trophoblast cells: the facts Mol. Hum. Reprod., October 1, 2005; 11(10): 719 - 722. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020